Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.330
Abstract: MYD88 (myeloid differentiation primary response 88) is mutated in the majority of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (LPL); but also, albeit less frequently, in other B-cell malignancies, including chronic lymphocytic leukemia (CLL). This suggests MYD88 as a… read more here.
Keywords: cll; lymphocytic leukemia; lymphoplasmacytic lymphoma; chronic lymphocytic ... See more keywords
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Blood Cancer Journal"
DOI: 10.1038/s41408-020-0277-6
Abstract: Activating MYD88 mutations promote pro-survival signaling through BTK and HCK, both targets of ibrutinib. Despite high response rates, complete responses to ibrutinib are lacking, and other MYD88 triggered pro-survival pathways may contribute to primary drug… read more here.
Keywords: pro survival; mutated myd88; syk; myd88 mutated ... See more keywords
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006147
Abstract: Key Points HCK facilitates TLR/BCR crosstalk through activation of SYK in response to mutated MYD88. The HCK inhibitor A419259 selectively blocks SYK activation in MYD88 mutated cell lines and primary WM lymphoplasmacytic cells. read more here.
Keywords: hck; syk activation; myd88 mutated; activation myd88 ... See more keywords